GLP-1 Showdown Set For Fall: Bydureon Gets New October Review Deadline
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk also announces it will start the 9,000-patient cardiovascular outcomes trial for competitor Victoza in the fall.
You may also be interested in...
Roche/Ipsen's Suspended Taspoglutide Could Be Another Diabetes Casualty
Roche's decision to halt dosing in a trial of the GLP-1 receptor agonist taspoglutide following an announcement of a major development delay illustrates the intensively competitive nature of the diabetes market
Roche/Ipsen's Suspended Taspoglutide Could Be Another Diabetes Casualty
Roche's decision to halt dosing in a trial of the GLP-1 receptor agonist taspoglutide following an announcement of a major development delay illustrates the intensively competitive nature of the diabetes market
Roche/Ipsen's Suspended Taspoglutide Could Become Another Diabetes Casualty
Roche confirms suspension of dosing in Phase III taspoglutide program after reporting safety problems in June. But Roche's pain could be a gain for the competing GLP-1 Bydureon from Lilly/Amylin/Alkermes.